Cigna Investments Inc. New Has $400,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Cigna Investments Inc. New cut its holdings in Moderna, Inc. (NASDAQ:MRNA) by 3.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,367 shares of the company’s stock after selling 130 shares during the period. Cigna Investments Inc. New’s holdings in Moderna were worth $400,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after purchasing an additional 5,129,800 shares during the period. Wellington Management Group LLP raised its holdings in Moderna by 28.8% in the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares during the period. Capital World Investors lifted its position in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares during the last quarter. Norges Bank bought a new stake in Moderna during the fourth quarter valued at about $347,565,000. Finally, Mawer Investment Management Ltd. boosted its holdings in Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after acquiring an additional 120,621 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 5.3 %

NASDAQ:MRNA traded up $4.37 during trading hours on Thursday, hitting $86.62. 3,964,276 shares of the stock were exchanged, compared to its average volume of 4,122,394. The company has a market capitalization of $33.20 billion, a P/E ratio of -5.25 and a beta of 1.67. The company has a quick ratio of 3.91, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $118.88 and its two-hundred day moving average is $114.11. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s quarterly revenue was down 29.9% compared to the same quarter last year. During the same quarter last year, the business earned ($3.62) earnings per share. On average, sell-side analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Insider Activity at Moderna

In other news, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now directly owns 5,726 shares in the company, valued at approximately $930,303.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 648 shares of Moderna stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $105,280.56. Following the transaction, the chief financial officer now owns 5,726 shares of the company’s stock, valued at approximately $930,303.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at approximately $859,486.56. The disclosure for this sale can be found here. Insiders have sold 366,238 shares of company stock worth $51,819,454 over the last ninety days. Company insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MRNA shares. Evercore ISI reissued an “in-line” rating and set a $120.00 price objective on shares of Moderna in a research report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their price target for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. UBS Group boosted their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Finally, Canaccord Genuity Group raised their price target on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $124.07.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.